Welcome to our dedicated page for Cadrenal Therapeutics SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Cadrenal Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Cadrenal Therapeutics's regulatory disclosures and financial reporting.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing CAD-1005, tecarfarin and frunexian for critical care cardiology and orphan cardiovascular conditions. For the six months ended June 30, 2026, it reported a net loss of $5.8 million, an improvement from $7.5 million a year earlier, as total operating expenses fell 24% to $5.9 million. Cash used in operations was $5.2 million.
At June 30, 2026, Cadrenal held $2.4 million in cash and cash equivalents, total assets of $5.6 million and stockholders’ equity of $4.1 million, with an accumulated deficit of $44.8 million. Management states that expected operating losses and capital needs will exceed existing cash, raising substantial doubt about its ability to continue as a going concern without additional financing. The company raised capital through an April 2026 warrant exercise and a June 2026 PIPE and is pursuing further equity, debt, grants and partnerships while prioritizing early- to mid-stage validation and out-licensing rather than self-funding Phase 3 trials.
Cadrenal Therapeutics, Inc. reported second quarter 2026 results and outlined progress in its Cardiac Acute Critical Care Franchise and strategic partnering efforts. For the quarter ended June 30, 2026, the company recorded a net loss of $3.3 million on total operating expenses of $3.3 million, both slightly improved versus 2025.
For the six months ended June 30, 2026, total operating expenses were $5.9 million compared with $7.7 million a year earlier, and the net loss narrowed to $5.8 million from $7.5 million, reflecting lower research and development spending. As of early August 2026, Cadrenal held approximately $4.2 million in cash and cash equivalents and expects its resources to fund operations through the first quarter of 2027.
The company states that existing cash resources are not sufficient to advance product candidates to clinical trial readiness or to commence and complete clinical trials and that it does not plan to start a trial unless funding sufficient to complete that trial is secured, potentially via partnerships, out-licensing, grants, or financings.
Cadrenal Therapeutics, Inc. reports that The PNC Financial Services Group, Inc., through its subsidiary PNC Bank, National Association, holds a beneficial position in the company’s common stock.
PNC reports beneficial ownership of 233,219 shares of Cadrenal common stock, representing 8.13% of the class as of June 30, 2026. PNC has sole voting and dispositive power over these shares, with no shared voting or dispositive power. The shares are held in a fiduciary account at PNC Bank for a client, identified as Daniel Maltz, who has the right to receive dividends and sale proceeds from this more-than-5% position.
Cadrenal Therapeutics, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on several governance and capital proposals.
Items include electing one Class I director, ratifying WithumSmith+Brown, PC as auditor for 2026, and amending the 2022 Successor Equity Incentive Plan to add 323,542 shares, bringing the plan reserve to 1,000,000 shares. Stockholders are also asked to approve, under Nasdaq Rule 5635(d), the potential issuance of up to 960,000 shares upon exercise of Series C-1 warrants issued in a July 1, 2026 private placement, and to permit adjournment if more time is needed to solicit votes on the equity plan or warrant proposals. There were 3,567,592 shares of common stock outstanding and entitled to vote as of July 27, 2026, and the board recommends voting FOR all proposals.
Cadrenal Therapeutics, Inc. is calling a virtual annual stockholder meeting on September 24, 2026. Stockholders of record as of July 27, 2026 will vote on five proposals.
The agenda includes electing Quang X. Pham, the current Chairman and CEO, as the sole Class I director for a term running to the 2029 annual meeting, and ratifying WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2026. Stockholders are also asked to approve an amendment to the 2022 Successor Equity Incentive Plan to increase shares available for awards by 323,542 shares, bringing the plan’s share reserve to 1,000,000 shares. Another proposal seeks approval under Nasdaq Rule 5635(d) for the potential issuance of up to 960,000 shares of common stock upon exercise of Series C‑1 warrants issued in a July 1, 2026 private placement. A further proposal would permit adjournment of the meeting to solicit additional proxies if needed for the equity plan or warrant proposals.
The board has four members, three of whom are deemed independent, and recommends a FOR vote on all proposals. The filing also details board committee structures, director compensation for 2025, and audit fees of $157,050 for 2025.
Cadrenal Therapeutics, Inc. reoriented its pipeline by creating a unified Cardiac Acute Critical Care Franchise and starting a structured process to pursue strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets.
The company highlighted late-breaking Phase 2 data for CAD-1005 presented at the ISTH 2026 Congress, showing a greater than 25% absolute reduction in thrombotic events with a favorable safety and renal-protective baseline. CAD-1005, a 12-LOX inhibitor for heparin-induced thrombocytopenia, has Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA. The franchise also includes frunexian, an IV Factor XIa inhibitor, and tecarfarin, an oral vitamin K antagonist being advanced for chronic anticoagulation indications and rare pediatric disease protocols that the company states could potentially qualify for a Priority Review Voucher. Beyond the franchise, Cadrenal is progressing CAD-2000, an oral 12-LOX inhibitor for chronic cardiorenal inflammatory and thrombotic indications, as a companion to its IV acute care platform.
Cadrenal Therapeutics, Inc. is registering for resale up to 2,942,400 shares of common stock for existing holders of warrants issued in a July 1, 2026 private investment in public equity (PIPE) and related placement agent compensation. The company itself is not selling any shares under this prospectus and receives no proceeds from stockholder resales.
The registered shares consist of 2,880,000 shares issuable on exercise of pre-funded and Series C-1/C-2 warrants sold to a single institutional investor and 62,400 shares issuable on exercise of placement agent warrants. If all investor and placement agent warrants are exercised for cash, Cadrenal would receive about $6.0 million, intended for working capital and general corporate purposes, in addition to the approximately $3.0 million gross proceeds already received in the PIPE.
Common stock outstanding was 3,098,592 shares as of July 10, 2026, and would be 6,040,992 shares if all related warrants are fully exercised. The company highlights significant financing needs, potential dilution, substantial resale volume (up to roughly half of current shares), warrant-related constraints, and an auditor’s going concern explanatory paragraph as key risks.
Cadrenal Therapeutics, Inc. entered into a confidential separation agreement and general release with Chief Medical Officer Dr. James J. Ferguson III, following his previously reported resignation effective July 31, 2026.
Dr. Ferguson will receive salary through the Separation Date, reimbursement of approved unreimbursed business expenses, and company payment of COBRA medical premiums for up to six (6) months after the Separation Date for himself and eligible dependents, subject to ongoing COBRA eligibility and loss of benefits if he becomes eligible for new employer coverage. The agreement includes a broad release of claims and a non-disparagement clause and becomes effective only after two separate seven-day revocation periods, one after he signs the agreement and another after he signs a second release on the Separation Date.